11 results · 28ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

KLEIN MICRO-CANNULA(TM)

FDA 510(k)
FDA Class 1 ·General, Plastic Surgery

Map-iT

FDA UDI
ACCESS POINT TECHNOLOGIES, INC.·00818087020077·Steerable Decapolar Catheter, Multi-Purpose D C...

SURE-T PARADIGM

FDA Adverse Event
Malfunction ·UNOMEDICAL A/S·Product code FPA·July 4, 2024

ZYNO MEDICAL Z-800 INFUSION PUMP SYSTEM

FDA Adverse Event
Malfunction ·ZYNO MEDICAL, LLC·Product code FRN·December 9, 2020

ANY PLUS SPINAL FIXATION SYSTEM

FDA 510(k)
FDA Class 2 ·Orthopedic

MICOR CONDUCTION CATHETER

FDA 510(k)
FDA Class 2 ·Anesthesiology

BD CATHENA¿ SAFETY IV CATHETER

FDA Adverse Event
Malfunction ·BECTON DICKINSON MEDICAL (SINGAPORE)·Product code FOZ·May 19, 2022

CUSA EXCEL 36 KHZ CURVED EXTENDED STANDARD TIP

FDA Adverse Event
Malfunction ·INTEGRA LIFESCIENCES IRELAND LIMITED·Product code LFL·May 5, 2014

SENSIA SR

FDA Adverse Event
Death ·MEDTRONIC MED REL, INC.·Product code NVZ·November 17, 2010

TOTAL ASR FEM IMP SIZE 45

FDA Adverse Event
Injury ·DEPUY INTERNATIONAL·Product code KXA·January 8, 2013

Assurity Model Numbers: PM1240, PM2240; Assurity + Model Number: PM2260; Accent Model Numbers: PM1210, PM2210, PM1222, PM2212; Accent MRI Model Numbers: PM1224, PM2218, PM2224 Implantation of a single-chamber pulse generator, dual-chamber pulse generator, or CRT-P is indicated in one or more of the following permanent conditions: Syncope, Presyncope, Fatigue, Disorientation, Or any combination of those symptoms. Implantation of a CRT-P is indicated for: Maintaining synchrony of the left and right ventricles in patients who have undergone an AV nodal ablation for chronic atrial fibrillation and have NYHA Class II or III heart failure. The reduction of the symptoms of moderate to severe heart failure (NYHA Class III or IV) in those patients who remain symptomatic despite stable, optimal medical therapy, and have a left ventricular ejection fraction d35% and a prolonged QRS duration

FDA Enforcement
Class II ·Terminated·St Jude Medical Inc.·October 25, 2017